MedTrace Logo

Luteolin for the Treatment of People With Schizophrenia

NCT05204407 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2026-04-22

No results posted yet for this study

Summary

Luteolin is a natural product found in foods such as celery, green pepper, parsley, and chamomile tea. It has been found to have anti-cancer, anti-oxidant, and anti-inflammatory properties. The purpose of this study is to determine if luteolin helps improve symptoms of schizophrenia.

Conditions

Interventions

DIETARY_SUPPLEMENT

Placebo

The placebo target dose will be 300 mg BID taken over 12 weeks in capsule form

DIETARY_SUPPLEMENT

Luteolin

The luteolin target dose will be 300 mg BID taken over 12 weeks in capsule form

Sponsors & Collaborators

Principal Investigators

  • Deanna Kelly, PharmD · University of Maryland, Baltimore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-13
Primary Completion
2026-01-14
Completion
2026-01-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05204407 on ClinicalTrials.gov